已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Neoadjuvant treatment with trastuzumab and pertuzumab plus palbociclib and fulvestrant in HER2-positive, ER-positive breast cancer (NA-PHER2): an exploratory, open-label, phase 2 study

医学 帕妥珠单抗 帕博西利布 曲妥珠单抗 富维斯特朗 内科学 乳腺癌 肿瘤科 新辅助治疗 转移性乳腺癌 癌症 雌激素受体 临床终点 临床试验
作者
Luca Gianni,Giancarlo Bisagni,Marco Colleoni,Lucia Del Mastro,Claudio Zamagni,Mauro Mansutti,Milvia Zambetti,Antonio Frassoldati,Raffaella De Fato,Pinuccia Valagussa,Giuseppe Viale
出处
期刊:Lancet Oncology [Elsevier BV]
卷期号:19 (2): 249-256 被引量:172
标识
DOI:10.1016/s1470-2045(18)30001-9
摘要

In the neoadjuvant setting, blockade of HER2 plus use of an aromatase inhibitor in patients with HER2-positive and oestrogen receptor (ER)-positive breast cancer leads to a pathological complete response in 21% of patients. Convergence of HER2 and ER signals on RB1 suggests that a combined pharmacological intervention directed to these targets could be synergistic. To test this approach, we combined palbociclib to block RB1, fulvestrant to block ER, and trastuzumab with pertuzumab to block HER2 in patients with HER2-positive, ER-positive breast cancer.NA-PHER2 is a multicohort, open-label, exploratory, phase 2 study done at seven sites in Italy. Patients were eligible for the first cohort if they had previously untreated, histologically confirmed, unilateral, invasive, HER2-positive, ER-positive breast cancer and were suitable for neoadjuvant therapy. Patients were treated every 3 weeks with intravenous trastuzumab (8 mg/kg loading dose followed by 6 mg/kg) and intravenous pertuzumab (840 mg loading dose in the first cycle and then at 420 mg) for six cycles plus oral palbociclib (125 mg once a day for 21 days in a 4-week cycle) and intramuscular fulvestrant (500 mg) every 4 weeks for five cycles. The coprimary endpoints were change from baseline in Ki67 expression at 2 weeks of treatment and at surgery (16 weeks after treatment) and changes in apoptosis from baseline to surgery. Secondary endpoints were clinical objective response (according to modified Response Evaluation Criteria in Solid Tumors) and pathological complete response. All patients who met eligibility criteria were assessed for the primary and secondary endpoints. All patients who received at least one cycle of therapy were assessed for safety. This trial is registered with ClinicalTrials.gov, number NCT02530424. The trial is ongoing and two further cohorts are being enrolled.Between May 20, 2015, and Feb 8, 2016, we enrolled 36 patients, of whom one was deemed ineligible for the study and five were found to be HER2-negative on retrospective analysis. Thus, 35 patients were included in safety analyses and 30 were assessed for the primary and secondary endpoints. At baseline, geometric mean Ki67 expression was 31·9 (SD 15·7), versus 4·3 (15·0) at week 2 (n=25; p<0·0001) and 12·1 (20·0) at time of surgery (n=22; p=0·013). The geometric mean for apoptosis was 1·2 (SD 0·3) at baseline versus 0·4 (0·4; p=0·019) at surgery. A clinical objective response immediately before surgery was achieved by 29 (97%; 95% CI 83-100) of 30 patients. At surgery, eight (27%; 95% CI 12-46) patients had a pathological complete response in breast and axillary nodes. The most frequent grade 3 adverse events were neutropenia (ten [29%]), diarrhoea (five [14%]), and stomatitis, increased alanine aminotransferase, and hypersensitivity reactions (one [3%] of each event). No grade 4 or serious adverse events were recorded in the study and there were no deaths.The combination of palbociclib, fulvestrant, trastuzumab, and pertuzumab had a significant effect on the expression of Ki67 at 2 weeks and at surgery. Triple targeting of ER, HER2, and RB1 in HER2-positive and ER-positive breast cancer could be an effective chemotherapy-free treatment strategy. Further clinical testing and additional molecular characterisation is necessary, not only in hormone receptor-positive tumours but also in tumours without HER2 amplification.Pfizer and Roche.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
mmmm发布了新的文献求助10
2秒前
soso完成签到 ,获得积分10
3秒前
3秒前
王木木完成签到 ,获得积分10
4秒前
小李新人发布了新的文献求助10
4秒前
ket的应助被一颗柿子树采纳,获得30
4秒前
sortie完成签到,获得积分10
7秒前
曹大壮完成签到,获得积分10
10秒前
林余发布了新的文献求助10
10秒前
露稚完成签到 ,获得积分10
10秒前
lzp完成签到 ,获得积分10
13秒前
王胜楠发布了新的文献求助10
15秒前
小巧念露完成签到,获得积分10
18秒前
土书完成签到,获得积分10
18秒前
19秒前
彭于晏的应助被科研通管家采纳,获得10
20秒前
笙笙的应助被科研通管家采纳,获得10
20秒前
斯文败类的应助被科研通管家采纳,获得10
21秒前
21秒前
万能图书馆的应助被上善若水采纳,获得10
21秒前
笙笙的应助被科研通管家采纳,获得10
21秒前
汉堡包的应助被科研通管家采纳,获得10
21秒前
田様的应助被科研通管家采纳,获得10
21秒前
ffff完成签到 ,获得积分10
25秒前
兰高锋发布了新的文献求助30
25秒前
温暖无招完成签到 ,获得积分10
29秒前
17完成签到,获得积分10
29秒前
贪玩千儿完成签到,获得积分10
31秒前
liza发布了新的文献求助10
35秒前
爆米花的应助被YCLING采纳,获得10
35秒前
JamesPei的应助被wjw采纳,获得30
39秒前
nanfeng完成签到 ,获得积分10
42秒前
陶醉成协完成签到,获得积分10
42秒前
隐形曼青的应助被刻苦乐天采纳,获得10
42秒前
黎明深雪完成签到 ,获得积分10
44秒前
鲅鱼饺子完成签到 ,获得积分10
45秒前
热情的水杯完成签到,获得积分10
45秒前
如梦完成签到 ,获得积分10
46秒前
Hello的应助被旺仔仔采纳,获得10
46秒前
49秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8184917
求助须知:如何正确求助?哪些是违规求助? 9573843
关于积分的说明 21833352
捐赠科研通 7782304
什么是DOI,文献DOI怎么找? 3434429
关于科研通互助平台的介绍 2558581
邀请新用户注册赠送积分活动 2481082